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SUMMARY
Following cessation of continuous Ebola virus
(EBOV) transmission within Western Africa, sporadic
EBOV disease (EVD) cases continued to re-emerge
beyond the viral incubation period. Epidemiological
and genomic evidence strongly suggests that this
represented transmission from EVD survivors. To
investigate whether persistent infections are charac-
terized by ongoing viral replication, we sequenced
EBOV from the semen of nine EVD survivors and a
subset of corresponding acute specimens. EBOV
evolutionary rates during persistence were either
similar to or reduced relative to acute infection rates.
Active EBOV replication/transcription continued dur-
ing convalescence, but decreased over time, consis-
tent with viral persistence rather than viral latency.
Patterns of genetic divergence suggest a moderate
relaxation of selective constraints within the sGP car-
boxy-terminal tail during persistent infections, but do
not support widespread diversifying selection. Alto-
gether, our data illustrate that EBOV persistence in
semen, urine, and aqueous humor is not a quiescent
or latent infection.
INTRODUCTION
From December 2013 to June 2016, Sierra Leone, Guinea and
Liberia experienced an Ebola virus (EBOV) outbreak causing
28,646 confirmed, probable, and suspected Ebola virus dis-
ease (EVD) cases—including 11,323 deaths and over 10,000
EVD survivors (WHO, 2016a). Despite the World Health Orga-
nization (WHO) declaring these countries disease-free 42 days
(twice the 21-day viral incubation period) after the last active
case, sporadic EVD cases continued to appear outside of
this window and several reports strongly suggest that these
unexpected re-emergences occurred due to viral transmission
from persistently infected EVD survivors (Arias et al., 2016;
Blackley et al., 2016; Christie et al., 2015; Diallo et al., 2016;
Mate et al., 2015; Sissoko et al., 2017b). Other possible expla-
nations, later discarded, included that sporadic cases could
represent a missed transmission chain, reintroduction from
an animal reservoir, or from another geographical location.
Genetic data and phylogenetic analysis have been critical to-
ward a resolution among these possibilities.
Filovirus persistence was initially observed with a single
Marburg virus sexual transmission case in 1967 (Martini and
Schmidt, 1968). Very scarce data from previous outbreaks sug-
gested a prolonged presence of EBOV nucleic acids in semen
and other bodily fluids collected from convalescent patients
(Bausch et al., 2007; Rodriguez et al., 1999; Rowe et al., 1999).
Recent EVD persistence studies in Sierra Leone, Liberia, Guinea,
and the United States extended these observations and defini-
tively demonstrated that EBOV RNA can be detected within
the semen of EVD survivors months to 2 years after recovery,
and live virus can be isolated from a subset of these specimens
(Barnes et al., 2017; Deen et al., 2017; Sissoko et al., 2017a;
Soka et al., 2016; Uyeki et al., 2016). Initially, the WHO and
Me´decins Sans Frontie`res (MSF) advised male survivors to
abstain from sexual intercourse or use barrier protection for
3 months after recovery (Sterk, 2008; WHO, 2014), however,
based on results from the current outbreak (Christie et al.,
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2015; Deen et al., 2017; Mate et al., 2015), theWHO revised their
recommendations to include periodic EBOV RT-PCR semen
testing and for survivors that cannot access EBOV RT-PCR
semen testing, they should continue to practice safe sex for at
least 12months after the onset of symptoms (WHO, 2016b). Viral
recrudescence outside of the male genital tract (MGT) can also
develop after filovirus infection, as initially observed in 1977 for
a single case of Marburg virus uveitis (Kuming and Kokoris,
1977). During the West African outbreak, recrudescent cases
were again observed within the eye, and also the CNS several
months after initial infection (Jacobs et al., 2016; Varkey et al.,
2015). Altogether, these data suggest that after recovery from
EVD, EBOV can still persist within immune-privileged sites in
EVD survivors.
While much work has been done to explore themolecular evo-
lution of EBOV during acute infection (Dudas et al., 2017; Gire
et al., 2014; Ladner et al., 2015; Park et al., 2015; Simon-Loriere
et al., 2015; Tong et al., 2015), little is known about the dynamics
of persistent EBOV infections within immune-privileged niches.
Genomes from EVD flare-ups linked to transmission from persis-
tent infections exhibited reduced genetic divergence (Blackley
et al., 2016; Diallo et al., 2016). These low levels of divergence
could help to define and predict whether new outbreaks are
the result of transmission from individuals with acute or persis-
tent infections—such data could influence and guide future
epidemiological investigations. Furthermore, the extraordinary
discovery that EBOV can persistently infect immune-privileged
sites for several months opens significant questions regarding
viral replication mechanisms and the selective pressures experi-
enced during acute and persistent infection.
To address these questions, we directly sequenced EBOV
RNA from clinical specimens collected during acute EVD and
during EVD convalescence (‘‘persistence’’) (Figure S1A). Using
these EBOV sequences, we directly estimated viral evolutionary
rates during persistent infection. We observed significant reduc-
tions in the rate of viral evolution within a subset of persistent in-
fections, while others exhibited acute-like rates, and we present
potential mechanisms to explain these results. We also exam-
ined patterns of selection during persistent infection and demon-
strate that active viral replication/transcription continues during
viral persistence.
RESULTS
EBOV in Semen Specimens from Sierra Leonean EVD
Survivors Exhibits Reduced Evolutionary Rates
Using a random subset of acutely acquired viral sequences
(AAVS) from specimens collected from May 2014–September
2015 and sequenced directly from blood, plasma, or oral swab
specimens from EVD patients with acute symptoms in Sierra
Leone, we inferred a mean evolutionary rate of 0.963 103 sub-
stitutions/site/year ([0.86–1.063 103] 95%credible interval) un-
der the uncorrelated lognormal (UCLN) model of rate variation
among branches. These acute rate estimates are similar to pre-
viously reported rate estimates (Gire et al., 2014; Park et al.,
2015; Simon-Loriere et al., 2015; Tong et al., 2015). Using Bayes
factor values calculated from path and stepping-stone sampling,
the UCLN relaxed clock models were the best fit to the data,
however, evolutionary rate estimates were also similar under
the fixed local clock model (Figure S1B; Table S1).
Most semen-acquired viral sequences (SAVS) exhibited lower
genetic divergence, given their sampling time, than the mean
AAVS divergence, although in all cases, this divergence was in-
side the prediction interval calculated for AAVS (Figure 1A). The
average collection period for SAVS was 170 days post disease
onset with a range of 82–322 days. During these collection pe-
riods, SAVS exhibited a significantly reduced evolutionary rate
compared to AAVS (Figure 1B). Reversion of potential U-to-C hy-
per-edited sites, whichmay be the result of host ADAR enzymes,
similar to Dudas et al. (2017), slightly decreased the acute evolu-
tionary rate (0.893 103 subs/site/year, [0.80–0.993 103] 95%
credible interval), as expected (Figure 1A). After removal of hy-
per-edited sites, SAVS exhibited amarginally significant reduced
evolutionary rate compared to AAVS (Figure 1B).
EBOV Evolutionary Rates from Paired Acute and
Convalescent Clinical Specimens
Serial specimens acquired from US EVD survivors permitted a
comparison of viral sequences acquired during acute and persis-
tent infectionwithin a single individual. For all US survivors, AAVS
were nearly identical and exhibited genetic divergence consis-
tent with other AAVS collected during the outbreak (Figures 2A
and S1C). For survivor C, concurrent viral compartmentalization
was observed in the eye and MGT, and we did not observe evi-
dence of viral exchange between these sites (Figure S1C). Using
the UCLN relaxed clock model, mean posterior rate estimates
fromUSAAVS (estimated over an average of 5 days)were slightly
decreased, but not significantly different to rate estimates from
other AAVS collected during the outbreak (estimated over
542 days) (Figure 2B; Table S1). In contrast to SAVS collected
from EVD survivors in Sierra Leone, SAVS collected from US
EVD survivors exhibited a mean evolutionary rate estimate that
was 1.45-fold greater than acute rate estimates (Figure 2B;
Table S1). We attribute this rate increase to U-to-C hyper-editing
that occurred during viral persistence in survivors A and C (Fig-
ures 2A and 2C). Reversion of U-to-C hyper-edits from all se-
quences reducedUSsurvivor AAVS andSAVSevolutionary rates
to a level that was similar to acute-infection rate estimates (Fig-
ures 2A and 2B). While US EVD survivors received multiple ther-
apeutic EVD treatments during early disease, we did not observe
anymutationswithin viral regions (GP, VP35, L) targeted by these
compounds (Supplemental Experimental Procedures). Thus, we
hypothesize that these de novo U-to-C hyper-edits are not the
result of therapeutic EVD treatments. U-to-C hyper-editing was
also observed in Sierra Leone survivors 1 and 5, but from the
available specimens, we cannot determine whether these
changes occurred de novo during viral persistence, or during
acute infection, because other AAVS from Sierra Leone (SLE)
share the same set of mutations (Figure 2C).
U-to-C hyper-editing is not unique to SAVS, similar patterns
have also been observed within AAVS (Dudas et al., 2017; Ni
et al., 2016; Park et al., 2015; Smits et al., 2015; Tong et al.,
2015), however, it is currently unknown whether acute- and
persistence-specific hyper-edited genomic regions exist. Here,
we observed that most acute editing occurred within non-coding
regions and the highest rates of hyper-editing were on the
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30 untranslated NP and VP40 transcripts. (Figure 2C). The distri-
bution of hyper-edited sites in Figure 2C represents a combina-
tion of both de novo and ancestrally acquired hyper-edits. In
contrast to AAVS, edited sites in SAVS are only within a distinct
region on the 30 untranslated NP transcript (Figure 2C). Hyper-
mutation within this region was also observed with high fre-
quency within AAVS and is near a U-to-C editing site (3008-11)
that can upregulate NP transcription (Figure 2C) (Ni et al.,
2016). Because ADAR editing deaminates adenosine to inosine,
which base pairs with cytidine, canonical ADAR editing typically
results in A/ G mutations on the affected strand (Bass, 2002).
Therefore, these U-to-C hyper-edits likely reflect ADAR editing of
the viral (RNA) genome.
Selective Pressures within Immune-Privileged Sites
Because immune-privileged sites represent a unique niche,
EBOV may experience selective pressure differences during
acute and persistent infection. Selective pressures during acute
infection were first estimated using Bayesian robust counting
and compared to phylogenetic analysis by maximum likelihood
(PAML) branch- and branch-site-specific models. To prevent
rate overestimation by double-counting shared amino acids,
the glycoprotein was split at the transcriptional editing site into
N-terminal (NGP), C-terminal full-length (GP1 carboxy-terminus
and GP2, CGP), and secreted GP (SGPc), and rates were esti-
mated independently for each protein fragment (Figure 4). In-
ferred selective pressures were similar when estimated using
Bayesian robust counting (AAVS only) and paml modeling
(AAVS and SAVS) (Figure 3). In general, u estimates were similar
to or reduced compared to previous robust counting estimates
(Park et al., 2015; Tong et al., 2015), consistent with purifying se-
lection acting over a longer time period (Figure 3A). A comparison
of the changes accumulated in the cohort, including its analysis
in the context of the larger outbreak, did not reveal significant dif-
ferences among groups (Figure S2; Table S2).
Using the branch model, a moderate increase in u was
observed for the carboxy-terminal secreted glycoprotein tail
(sGPc) (p = 6.13 3 10
5) of SAVS (Figure 3B; Table S2). This
data were supported by the branch-site model, which provided
evidence of site-based positive selection in SAVS occurring at
Figure 1. EBOV in Semen Specimens from Sierra Leonean EVD
Survivors Exhibit Reduced Evolutionary Rates
(A) Genetic divergence versus specimen collection date for nearly all SLE
viral sequences (n = 1,058) acquired from blood, plasma, or oral swab during
acute infection (gray) and from semen during persistent infection (color).
Colored bars represent survivor-reported symptom onset dates, and red
whiskers represent onset date ambiguity for survivor 3. Top: includes se-
quences without editing. Bottom: includes sequences with reversion of po-
tential U-to-C hyper-edited sites. Acute specimen average divergence from
root is black dashed line and corresponding 95% confidence interval is gray
(along black dashed line). Dotted lines represent 95% prediction intervals.
EVD survivors 1, 2, 3, and 4 exhibited a reduced number of substitutions
relative to the mean AAVS divergence, whereas survivors 5 and 6 exhibited
an increased number of substitutions relative to the mean AAVS divergence
(upper panel). Removal of hyper-edited sites reduced the number of sub-
stitutions for patient 5 (bottom).
(B) SAVS exhibit significantly reduced evolutionary rates compared to AAVS.
Posterior rate distribution differences of SAVS compared to AAVS using un-
edited sequences (solid line) and reversion of potential hyper-edited sites
(dashed line). Shaded density tails indicate 95% highest posterior density in-
terval (HPD) and black dotted line indicates the expectation that rate estimates
are identical during acute and persistent infection.
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glycoprotein amino acid residues 296N (CGP) (posterior proba-
bility 99.9%), 296T (sGPc) (posterior probability 99.9%), and
315P (sGPc) (posterior probability 78.2%) (Figure 3C). However,
these mutations were each detected in only one EVD survivor
(survivor 2: 296N/T and survivor 4: 315P), and thus likely
represents an overestimation of u in SAVS. Therefore, we hy-
pothesize that nonsynonymous changes in sGPc from SAVS
(Figure 3B) are suggestive of the relaxation of selection con-
straints, rather than evidence of positive selection at specific
sites.
Additional unique glycoprotein mutations were observed dur-
ing viral persistence that were not accurately captured by the
PAML analysis. SAVS from survivor 2 contained an insertion in
the GP transcriptional editing site (A / AC, 296N/T above)
Figure 2. EBOV Sequenced from Acute and Persistent Clinical Specimens Acquired from US EVD Survivors Exhibits Acute-like Evolutionary
Rates
(A) Genetic divergence versus specimen collection date for viral sequences from US EVD survivors and 1,498 sequences from SLE, Guinea (GIN), and Liberia
(LBR). Left: includes sequences without editing. Right: includes sequences with reversion of potential hyper-edited sites. Viral sequences were acquired from
blood, plasma, or oral swab specimens during acute infection (gray), or from blood, plasma, semen, urine, or eye during acute and persistent infection in EVD
survivors (color). Mean divergence, 95% confidence interval, and 95% prediction intervals as in Figure 1.
(B) Prior to removal of hyper-edited U-to-C sites, SAVS (green solid line) exhibit1.45-fold increased evolutionary rate compared to AAVS (orange solid line). After
reversion of U-to-C hyper-edits, SAVS (green dashed line) exhibit a similar divergence as AAVS (orange dashed line). Overall, AAVS and SAVS evolutionary rates
were not significantly different from the overall acute evolutionary rate (black dotted line, estimated fromAAVS collected in SLE, GIN, and LBR). HPD intervals and
rate distribution difference as in Figure 1.
(C) Distribution of U-to-C hyper editing sites using 1,498 sequences from SLE, GIN, and LBR. Occurrence of hyper-editing across the viral genome (black bars)
and within coding regions (gray shading). GP transcriptional editing is dotted line, and GP1 and GP2 cleavage is dashed line. Hyper-edited sites from EVD
survivors versus days post symptom onset is right y axis (blue). These sites only occurred within a distinct region near the untranslated 30 nucleoprotein (NP)
transcript, which was also observed with high frequency within acute specimens and is near a U-to-C editing site described in Ni et al. (2016) (red bar).
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that shifts the reading frame and results in a viral genome encod-
ing for the full-length GP tail, rather than the canonical sGP tail
(Figures 3C and S2A site 6924; Table S2). This insertion was pre-
sent in all 7 semen specimens from this patient, but its frequency
in the SAVS population varied (34%–65%, Figures S2A–S2C).
This insertion was also maintained in viral isolates (EBOV grown
in tissue culture cells inoculated with survivor 20s semen speci-
mens) (data not shown), suggesting that it represents a true
genomic mutation and not an overrepresentation of edited
mRNA in consensus genomes. Interestingly, the end result of
this change resembles the 7U/8U mutation that is induced by
passage of some strains of EBOV (Zaire, Sudan) in Vero cell lines
(Alfson et al., 2015; Volchkova et al., 2011). Additionally, survivor
3 contained a SNP that resulted in the loss of the sGP stop
codon, which extends the sGP tail by an additional 66 amino
acids (Figure 3C).
Evidence of Active Viral Replication within Semen
Specimens from EVD Survivors
Currently there is limited data as to the extent of active viral repli-
cation during EBOV persistence and whether this replication oc-
curs with intact or defective viral genomes. Through the use of
stranded sequencing and qRT-PCR approaches, we were able
to further define the strandedness of viral nucleic acids produced
during acute and persistent infection (Figures 4, S3, and S4).
Several studies provide support for chronic viral infection occur-
ring due to the production of defective viral genomes (DVGs)
containing internal/copy-back deletions (Calain et al., 1999;
Li et al., 2011; Tapia et al., 2013) or terminal deletions (Meyer
and Schmaljohn, 2000; Meyer and Southern, 1997). Overall,
we observed similar depths of negative-sense (i.e., genomic)
genome coverage between AAVS and SAVS (Figure 4A). There-
fore, we do not see evidence for a preponderance of truncated
genomes. However, we did observe a small proportion of
chimeric reads containing deletions, duplications or copy back
mutations (Table S3). Altogether, we did not observe any consis-
tent trends in the proportion of chimeric reads per patient over
time or during acute and persistent infection.
During acute infection, the proportion of positive-sense viral
reads varied between 7%–23% (average ± SD: 16.5% ± 6.9%)
and during persistent infection between 7%–46% (average
16.0% ± 10.9%) (Figure 4B). As a control, during in vitro infection
with EBOV-ZsGreen we observed 78%–91% positive-sense
viral reads in themonolayer (compatible with the detection of pri-
marily mRNA) and 2%–5% positive-sense viral reads in the su-
pernatant (compatible with the detection of primarily genomic
RNA) at 18-48 hr post-infection (Figure S3A). Because SAVS
contained proportions of positive-sense reads similar to or
greater than that observed during acute infection, these data
demonstrate the presence of active transcription/replication in
all persistent survivor specimens studied herein.
During acute and persistent infections, the proportion of pos-
itive sense reads changed over time. As expected for acute
infection, there was an increase in the proportion of positive
sense reads over time, consistent with an increase in active viral
replication/transcription during EVD (Figure 4C). After recovery
Figure 3. Selective Pressures within
the MGT
(A) Comparison of loge(u) estimates for viral genes
calculated using PAML branch model (green) and
coalescent robust counting (orange, error bars
indicate 95% HPD) or from Park et al. (2015) (dark
gray, error bars indicate 95%HPD) and from Tong
et al. (2015) (light gray, error bars indicate 95%
HPD). Rate estimates in PAML/codeml used SAVS
and a subset of AAVS from SLE, GIN, and LBR
(collected between 03/2014–09/2015). Robust
counting estimates used a subset of AAVS from
SLE, GIN and LBR collected between 03/2014–07/
2015. Rate estimates from Park et al. (2015)
and Tong et al. (2015) were calculated using
robust counting with specimens collected be-
tween 03/2014–03/2015 and 03/2014–11/2014.
In most cases, u estimates closely agree and
were reduced compared to previous estimates,
consistent with purifying selection acting over a
longer time period. Branch and branch-site PAML
models support elevated u in the secreted GP
carboxy-tail from SAVS (‘‘SGPc’’) (stars). GP rate
estimates from Park et al. (2015) and Tong et al.
(2015) include full-length GP, rather than parti-
tioned GP, as analyzed here (+ sign).
(B) Comparison of the proportion of total nonsynonymous (N, gray) and synonymous (S, black) counts across AAVS (from SLE, GIN, and LBR) and SAVS tree
branches for the SGPc tail. Numbers above bars are the total count of N/S substitutions summed across AAVS and SAVS branches. Only nonsynonymous
substitutions were observed in SAVS within the SGPc tail.
(C) Comparison of the glycoprotein (GP) C-terminal variants produced following transcriptional RNA editing. Sites identified with the PAML branch-site model to
experience potential positive selection in SAVS are in gray and wild-type alleles are in red. Intervening amino acids (not to scale) are summarized with ‘‘..’’
Protease cleavage in the sGPc tail produces canonical sGPc and D peptide (red line) and cleavage of the full-length GP produces GP1 and GP2. Loss of the sGP
stop codon is predicted to produce an extended D peptide for survivor 3 (gray).
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Figure 4. Active Viral Replication during Persistent Infection
(A) Average normalized negative-sense (viral genome) coverage for AAVS and SAVS (coverage mean [line] and standard deviations [shading]).
(B) Proportion of EBOV genome-wide positive-sense reads out of total reads from EVD survivor specimens. Specimen types indicated by color, point shape
indicates virus isolation results and specimens in (D) contain thick borders. Blue dashed horizontal line indicates the proportion of positive-sense reads observed
from a negative-sense viral RNA in vitro transcript (Figure S3A).
(C) Proportion of positive-sense reads versus day post symptom onset for acute specimens (left) and persistent specimens (right). Patients highlighted by color,
virus isolation results highlighted by shape and nucleoprotein cycle threshold values highlighted by size.
(D) Proportion of normalized strand-specific reads per EBOV gene fromAAVS (left) or SAVS (right). Negative-sense (viral genome) reads in red, and positive-sense
(mRNA and viral complementary genome) reads in blue (shading is SE of the normalized coverage means).
1164 Cell Reports 22, 1159–1168, January 30, 2018
from EVD, the ratio of positive-sense reads generally decreased
logarithmically with time post onset (Figure 4C), however,
in some instances, the proportion of positive-sense reads
was higher during persistence than during acute infection (survi-
vors A, C, and 2)—consistent with NP expression from a single
survivor (Barnes et al., 2017). For a subset of clinical specimens,
we isolated live virus (Spengler et al., 2015; Uyeki et al., 2016;
U.S., unpublished data) and observed that the likelihood of
positive virus isolation decreased over time (Figures 4B and
4C) and was significantly associated (p < 0.1) with the proportion
of positive-sense reads (Figures S3B and S3C) and NP Ct value
(p < 0.03) (Figures S3D and S3E).
We also observed that the relative depth of positive- and nega-
tive-sense RNA coverage was consistent with the accepted
model of replication for viruses of the order Mononegavirales.
For AAVS, SAVS, and during an in vitro infection, we observed
a decrease in positive-sense coverage along the viral genome,
consistent with mRNA expression decreasing in a roughly linear
manner from the 50 to 30 end (Figures 4D, S3F, and S3G). In
contrast, there was a steady depth of negative-sense reads
across the genome for all specimens, consistent with this strand
being synthesized as a continuous RNA molecule (Figures 4D,
S3F, and S3G). Similar positive- and negative-sense RNA
expression patterns were observed for in vitro infected cells (Fig-
ures S3F–S3G). However, a slight increase in 50 negative-sense
read coverage was observed during in vitro infection (Figures
S3F–S3G), and we hypothesize that is due to interrupted/partial
negative strand synthesis during active replication.
DISCUSSION
Genomic analysis of EBOV sequences collected from acutely in-
fected and convalescent survivors has yielded important insights
into viral replication and selective pressures experienced during
acute and persistent infections. During convalescence, EBOV
evolutionary rates in the semen, aqueous humor, and urine
were either similar to or reduced relative to the rates observed
during acute infection in blood and plasma. During persistence,
active EBOV replication/transcription continued, but decreased
with time, consistent with viral persistence (i.e., long-term viral
genomemaintenancewith active transcription/replication) rather
than viral latency (i.e., long-term viral genome maintenance
without active replication and low/no transcription). Further-
more, viral persistence did not appear to be linked to defective
interfering particles with consistently truncated genomes atten-
uating wild-type infection (Calain et al., 1999; Li et al., 2011;
Meyer and Schmaljohn, 2000; Meyer and Southern, 1997; Tapia
et al., 2013). We did observe evidence for a minor population of
chimeric reads in both acute and persistent specimens, how-
ever, from these short read data, we were not able to estimate
the proportion of DVGs in the population, and it is currently un-
clear what role, if any, these DVGs may play during viral persis-
tence. Finally, EBOV does not appear to have experienced sub-
stantially different selective pressures during persistence within
immune-privileged niches (testes, eye) as compared to those
experienced during acute infections. However, we did observe
a moderate relaxation of selective constraints within the sGP
carboxy-terminal tail during persistence.
The dichotomy of evolutionary rates observed between the
Sierra Leone and US clinical specimens is of particular interest.
After reversion of U-to-C hyper-edited sites, Sierra Leonean
specimens, on average, exhibited a reduced evolutionary rate,
while US specimens exhibited an ‘‘acute-like’’ rate. Our observa-
tion that SAVS can exhibit a slowed evolutionary rate is in line
with a previous rate estimate from a single SAVS (Diallo et al.,
2016) and supports rate estimates obtained from sexual trans-
mission cases (Blackley et al., 2016). However, the observation
of an ‘‘acute-like’’ evolutionary rate during EBOV persistence is
a novel finding.
In general, substitution rates represent a complex product
of effective population size, mutation rate, generation time, and
viral fitness (Duffy et al., 2008). The US and Sierra Leone rate dif-
ferences are likely due to differences in semen collection times
post disease onset; US semen specimens were collected an
average of 61 (minimum [min]: 28, maximum [max]: 116) days
post onset, whereas Sierra Leonean semen specimens were
collected an average of 188 (min: 80, max: 321) days post onset.
An acute-like evolutionary rate reflects active ongoing viral repli-
cation during early convalescence, whereas the reduced rate
may indicate increased pruning of deleterious alleles by purifying
selection over time. However, additional factors such as a lower
population size, reduced mutation rate, increased generation
time, or reduced viral fitness could also contribute to a reduced
substitution rate. Because the proportion of positive-sense
reads decreases during convalescence, these rate differences
also reflect a corresponding decrease in active viral replication
over time. Within the MGT, active viral replication could be
reduced by the lowered temperatures of the testes, a replication
restriction, sequestration of viral nucleic acids into a cellular
compartment, and/or immune/apoptotic-mediated clearance.
Together, these factors will decrease the viral population size
and increase generation time. While immune-privileged sites
represent a novel niche, viral fitness differences likely do not
contribute to the observed evolutionary rate differences,
because we did not observe evidence for significant selective
pressure differences in coding regions between SAVS and
AAVS.
Viral nucleic acids during acute infection have been detected
within the MGT (Dejucq and Je´gou, 2001) and many viruses
can establish persistent infections within a range of host sites
(Randall and Griffin, 2017), however, despite this prevalence,
relatively little is known regarding viral evolution during the acute
to persistent transition. Previous studies comparing HIV se-
quences collected from paired blood/PBMCs or semen con-
tained evidence of either compartmentalization or exchange
between these two compartments in individual donors (Delwart
et al., 1998; Gupta et al., 2000) and those patients that exhibited
HIV compartmentalization also exhibited reduced genetic diver-
sity (Pillai et al., 2005). However, abnormally low evolutionary
rates for HIV and other viruses (HTLV-I, HTLV-II, SFV, GBV-C,
and some plant viruses) are commonly due to a latent viral infec-
tion, or slow clonal expansion following viral integration (Duffy
et al., 2008)—viral replication strategies that are distinct from
models of EBOV replication.
Here, we found that two US survivors (C and A) exhibited evi-
dence of de novo U-to-C hyper-editing in specimens acquired
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during viral persistence, which inflated the apparent viral evolu-
tionary rate and likely occurred due to host-mediated ADAR1
cytoplasmic editing. Similar excessive ADAR-mediated edits
within short regions were also observed within noncoding re-
gions of AAVS (Dudas et al., 2017; Ni et al., 2016; Park et al.,
2015; Tong et al., 2015), however, additional molecular studies
are needed to confirm that these hyper-edits are due to host en-
zymes, and/or occur at sites containing secondary structure,
and to evaluate the significance of these edits. Preliminary evi-
dence suggests that a U-to-C editing site (3008-11) near those
observed within SAVS can upregulate NP transcription (Ni
et al., 2016). In other models, loss of ADAR1 editing activity
can upregulate interferon-stimulated genes (Rice et al., 2012),
thus ADAR-editing of viral transcripts may represent a proviral
method to control protein production (hepatitis delta virus), or
enhance viral replication (HIV), or may act through an anti-viral
method to introduce excessive mutations (LCMV) (Ge´linas
et al., 2011; Zahn et al., 2007). Similar hyper-editing has also
been observed during in vitro replication for other viruses (influ-
enza,measles, respiratory syncytial, Epstein-Barr, and polyoma-
virus) (Iizasa et al., 2010; Kumar and Carmichael, 1997; Martı´nez
and Melero, 2002; Suspe`ne et al., 2011). Most strikingly, U-to-C
and G-to-A hyper-editing has been observed following persis-
tent measles infections in the brain 4 and 6 months after initial
disease (Baczko et al., 1993; Cattaneo et al., 1988), and a similar
pattern of U-to-C edits were observed on the NP 30 untranslated
region during in vitro Marburg infection (Shabman et al., 2014).
Viral genomes with hyperedits in the VP40 50 (viral genome
orientation) tail were observed in the Magazine Wharf area of
SLE after a disease-free 2-week period, potentially representing
re-emergence from an EVD survivor, although both of these
cases were also associated with ‘‘multiple high-risk contacts’’
(Smits et al., 2015; WHO, 2015). While there are some estab-
lished links between ADAR and interferon signaling (George
and Samuel, 1999; Pfaller et al., 2011; Rice et al., 2012), teasing
apart the pro- and anti-viral interactions, alongwith their relation-
ship to viral persistence, will be an important area for future
research.
Besides on-the-ground contact tracing, there are currently no
molecular signatures that would allow one to confirm whether
EBOV was transmitted through contact with an acute case or
from contact with an EVD survivor. Here, we observed that a de-
layed evolutionary rate (as suggested previously by Blackley
et al. [2016] and Diallo et al. [2016]) or U-to-C hyper-editing in se-
rial specimens could suggest transmission from persistently in-
fected EVD survivors. However, the absence of these molecular
markers does not eliminate persistently infected EVD survivors
as potential sources of viral transmission.
Altogether, our data illustrate that EBOV persistence in semen
and aqueous humor does not imply a quiescent or latent infec-
tion, but instead is an ongoing balance between natural selection
and genetic drift within a novel intra-host niche. EBOV persis-
tence within EVD survivors may act as a viral reservoir. Fortu-
nately, sexual transmission of EBOV from EVD survivors is a
rare mechanism for viral transmission. Ultimately, understanding
the mechanisms of viral persistence in immune-privileged sites
will lead to additional treatment options, clarify public health rec-
ommendations, and is critical to document whether future or
past outbreaks might be due to transmission from persistently
infected EVD survivors.
EXPERIMENTAL PROCEDURES
Experimental Model and Subject Details
Human Subjects
Through the joint Sierra Leone Ebola Virus Persistence study (SLEVPS) with
the Ministry of Health and Sanitation (MoHS) in Sierra Leone, WHO, China-
CDC, and CDC, we had access to semen specimens collected from EVD
survivors. The SLEVPS was reviewed and approved by the Sierra Leone Insti-
tutional ReviewBoard and theWorld Health Organization Ethical ReviewCom-
mittee. Acute and persistent specimens from US EVD survivors were collected
by their treating physicians and transported to the CDC for detection of viral
RNA. This sequencing project was determined by the CDC institutional human
subject advisor to be a non-research public health response activity, and insti-
tutional review board review was not required.
Method Details
Whole Genome Sequencing and Bioinformatics
RNA was extracted from blood and semen specimens and sequenced using a
modified version of the Illumina TruSeqRNAAccess Library Prep kit. EBOV ge-
nomes were assembled using custom scripts. Additional details are available
in the Supplemental Experimental Procedures.
Sequence Analysis
Viral evolutionary rate estimates were conducted using both linear regression
modeling and time-structured phylogenies. Additional sequence analysis was
conducted using custom-made scripts. Evolutionary selective pressures were
estimated using the renaissance counting method in beast/v1.8.2 and hypoth-
esis testing was performed using the codeml model in paml/v4.5. Additional
details are available in the Supplemental Experimental Procedures.
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